Pembrolizumab and Ipilimumab as Second-Line Therapy for Advanced Melanoma

J Clin Oncol. 2021 Aug 20;39(24):2637-2639. doi: 10.1200/JCO.21.00943. Epub 2021 Jun 17.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Humans
  • Ipilimumab / adverse effects
  • Melanoma* / drug therapy

Substances

  • Antibodies, Monoclonal, Humanized
  • Ipilimumab
  • pembrolizumab